Cargando…
Outcomes of Patients with Advanced Urothelial Carcinoma after Anti–programmed Death-(ligand) 1 Therapy by Fibroblast Growth Factor Receptor Gene Alteration Status: An Observational Study
BACKGROUND: Clinical outcomes of anti–programmed death‑(ligand) 1 (anti–PD-[L]1) therapy in patients with locally advanced or metastatic urothelial carcinoma (mUC) and fibroblast growth factor receptor alterations (FGFRa+) remain unclear; recent studies have reported either comparable or poorer outc...
Autores principales: | Rezazadeh Kalebasty, Arash, Benjamin, David J., Loriot, Yohann, Papantoniou, Dimitrios, Siefker-Radtke, Arlene O., Necchi, Andrea, Naini, Vahid, Carcione, Jenna Cody, Santiago-Walker, Ademi, Triantos, Spyros, Burgess, Earle F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9806713/ https://www.ncbi.nlm.nih.gov/pubmed/36601039 http://dx.doi.org/10.1016/j.euros.2022.11.001 |
Ejemplares similares
-
Erdafitinib for locally advanced or metastatic urothelial carcinoma
por: Siefker-Radtke, Arlene O, et al.
Publicado: (2022) -
Surrogate Endpoints as Predictors of Overall Survival in Metastatic Urothelial Cancer: A Trial-level Analysis
por: Ghali, Fady, et al.
Publicado: (2022) -
How to manage patients with suspected upper tract urothelial carcinoma in the pandemic of COVID-19?
por: Lee, Hsiang-Ying, et al.
Publicado: (2021) -
Validation and Reliability Testing of the EORTC QLQ-NMIBC24 Questionnaire Module to Assess Patient-reported Outcomes in Non–Muscle-invasive Bladder Cancer
por: Blazeby, Jane M., et al.
Publicado: (2014) -
The Significant Role of Depression in Elderly Patients with Bladder Cancer
por: Oserowsky, Alexander, et al.
Publicado: (2021)